What is Nabriva Therapeutics Book Value per Share?
Nabriva Therapeutics's book value per share for the quarter that ended in Jun. 2023 was $-5.05.
During the past 12 months, Nabriva Therapeutics's average Book Value Per Share Growth Rate was -137.70% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -78.90% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -67.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
During the past 10 years, the highest 3-Year average Book Value Per Share Growth Rate of Nabriva Therapeutics was 70.80% per year. The lowest was -78.90% per year. And the median was -54.90% per year.
During the past 10 years, the highest P/B Ratio of Nabriva Therapeutics was 5.44. The lowest was 0.17. And the median was 1.56.
Nabriva Therapeutics Book Value per Share Historical Data
The historical data trend for Nabriva Therapeutics's Book Value per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Nabriva Therapeutics's Book Value per Share
For the Biotechnology subindustry, Nabriva Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nabriva Therapeutics's PB Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nabriva Therapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Nabriva Therapeutics's PB Ratio falls into.
Nabriva Therapeutics Book Value per Share Calculation
Nabriva Therapeutics's Book Value Per Share for the fiscal year that ended in Dec. 2022 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.
Nabriva Therapeutics (OTCPK:NBRVF) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
Nabriva Therapeutics Book Value per Share Related Terms
Thank you for viewing the detailed overview of Nabriva Therapeutics's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Nabriva Therapeutics (Nabriva Therapeutics) Business Description
Nabriva Therapeutics PLC is a clinical stage biopharmaceutical company. Nabriva is engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The company has developed a product candidate, XENLETA, a semi-synthetic pleuromutilin antibiotic that is the first in its class for oral and IV administration in humans. XENLETA is designed to inhibit the synthesis of a specific protein on the bacterial ribosome. It operates in one reportable segment, which comprises the research and development of novel anti-infective agents to treat serious infections. The firm has commercial rights to two approved products, SIVEXTRO and XENLETA, as well as one development product candidate, CONTEPO.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NBRVF has been successfully added to your 